Supernus to Present at Cowen and Company Healthcare Conference in March
February 20 2014 - 7:30AM
Business Wire
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty
pharmaceutical company, today announced that the Company’s
management will provide a business update on the Company at the
Cowen and Company Healthcare Conference.
Presentation Date: Monday, March 3 Time: 1:30pm ET
Place: The Boston Marriott Copley Place Hotel, Boston, MA
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR™ (extended-release
topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in
ADHD, including ADHD patients with impulsive aggression. These
product candidates include SPN-810 for impulsive aggression in ADHD
and SPN-812 for ADHD.
Supernus Pharmaceuticals, Inc.Jack A. Khattar, President and
CEOorGregory S. Patrick, Vice President and
CFO301-838-2591orInvestor Contact:Cockrell Group,
877-889-1972investorrelations@thecockrellgroup.comcockrellgroup.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024